P75. Genetic engineering of T cells for increased homing to the tumor site
© Idorn et al; licensee BioMed Central Ltd. 2014
Published: 12 March 2014
Adoptive cell transfer (ACT) using in vitro expanded T cells from biopsy material represents a highly promising treatment of disseminated cancer. ACT in its present form is rather crude and improvements seem within reach. Recruitment of transferred lymphocytes to the tumor site is a crucial step in ACT efficacy; however, quite few T cells actually reach the tumor site upon administration. In the present pre-clinical study we have genetically engineered T cells aiming at increasing the homing of T cells by matching expression of chemokine receptors on T cells to chemokines secreted by the tumor, thus improving anti-tumor efficacy of ACT. By PCR analysis we found that several malignant melanoma (MM) cell lines showed expression of cytokines CXCL8/IL-8, CXCL12/SDF-1 and CCL2, which was confirmed by ELISA analysis of MM conditioned medium. Taking advantage of mRNA electroporation we successfully transfected T cells with mRNA encoding the chemokine receptors CXCR2 and chimeric receptor CXCR4-R2 on the cell surface, the latter expressing the intracellular region of CXCR2 allowing expression in T cells. Work is in progress, but so far chemokine receptor CXCR2 and chimeric receptor CXCR4-R2 transfected T cells are capable of migrating towards their ligands, CXCL8 and CXCL12 respectively, in in vitro transwell migration assays. In vitro studies on the transfection and function of the CXCR4 and CCR2-R2 chimeric receptors as well as in vivo migration studies have been initiated, and data will be presented at the meeting.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.